FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | 2). | 購回股份(或其他證券)但沒有註銷 | 303,367 | | | | | | | | 0.01 % | RMB | 65.96 | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | ...

沪指8月18日上涨0.85%，申万所属行业中，今日上涨的有29个，涨幅居前的行业为通信、综合，涨幅 分别为4.46%、3.43%。医药生物行业今日上涨1.07%。跌幅居前的行业为房地产、石油石化，跌幅分别 为0.46%、0.10%。 资金面上看，两市主力资金全天净流出160.57亿元，今日有8个行业主力资金净流入，电子行业主力资 金净流入规模居首，该行业今日上涨2.48%，全天净流入资金50.40亿元，其次是通信行业，日涨幅为 4.46%，净流入资金为49.04亿元。 主力资金净流出的行业有23个，非银金融行业主力资金净流出规模居首，全天净流出资金70.87亿元， 其次是电力设备行业，净流出资金为50.90亿元，净流出资金较多的还有医药生物、基础化工、房地产 等行业。 医药生物行业今日上涨1.07%，全天主力资金净流出47.06亿元，该行业所属的个股共474只，今日上涨 的有347只，涨停的有7只;下跌的有119只。以资金流向数据进行统计，该行业资金净流入的个股有155 只，其中，净流入资金超亿元的有7只，净流入资金居首的是塞力医疗，今日净流入资金1.52亿元，紧 随其后的是福瑞股份、新天药业，净流入资金分别 ...

医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 5.14 | 21.42 | 15167.42 | | 300049 | 福瑞股份 | 20.00 | 8.88 | 14112.13 | | 002873 | 新天药业 | 10.04 | 21.73 | 12756.46 | | 300003 | 乐普医疗 | 7.50 | 5.21 | 11879.51 | | 600645 | 中源协和 | 5.87 | 7.07 | 10630.01 | | 300204 | 舒泰神 | 3.85 | 5.17 | 10605.35 | | 688189 | 南新制药 | 20.03 | 13.24 | 10160.34 | | 000538 | 云南白药 | 1.57 | 1.14 | 7852.22 | | 600557 | 康缘药业 | 2.15 | 5.69 | 7699.12 | | 002082 | 万邦德 | 10.01 | 3.49 | ...

格隆汇8月18日丨药明康德(02359.HK)发布公告，2025年8月18日耗资2999.76万元人民币回购30.79万股 A股，回购价格每股96.65-99.12元。 ...

药明康德（603259）(02359)发布公告，于2025年8月18日斥资2999.76万元回购A股股份30.79万股，每股 回购价格为96.65-99.12元。 ...

智通财经APP讯，药明康德(02359)发布公告，于2025年8月18日斥资2999.76万元回购A股股份30.79万 股，每股回购价格为96.65-99.12元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 第 1 頁 共 12 頁 v 1.3.0 | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | 2). | 購回股份(或其他證券)但沒有註銷 | 303,367 | | | | | | | | 0.01 % | RMB | 65.96 | ...

Core Insights - The healthcare services sector experienced a rise of 1.26% on August 18, with a net outflow of 1.405 billion yuan in principal funds [1] - Among the constituent stocks, 33 increased in value while 9 decreased [1] Fund Flow Analysis - The top net outflows were recorded for WuXi AppTec at 478 million yuan, Innovent Biologics at 410 million yuan, and Kelun Pharmaceutical at 175 million yuan [1] - Other notable outflows included Sanbo Brain Science at 157 million yuan and Ruizhi Pharmaceutical at 54.73 million yuan [1] Stock Performance - Key stocks with significant performance included: - Kanglong Chemical with a price of 30.94 and an increase of 2.35%, attracting a net inflow of 68.68 million yuan [1] - Baihua Pharmaceutical at 8.78, up 10.03%, with a net inflow of 63.97 million yuan [1] - Aier Eye Hospital at 13.22, up 1.34%, with a net inflow of 784.89 thousand yuan [1] - Huakang Clean at 33.28, up 13.39%, with a net inflow of 3316.13 thousand yuan [1] - Tongce Medical at 46.18, up 2.26%, with a net inflow of 3071.04 thousand yuan [1]

Group 1 - The main focus of the article is on the significant outflow of capital from specific stocks as of August 18, with notable amounts listed for each company [1] - The top three companies with the highest capital outflow are: Wolong Electric Drive (-1.518 billion), Tianfeng Securities (-1.458 billion), and Dongfang Wealth (-1.100 billion) [1] - Other companies experiencing substantial outflows include: Quzhou Development (-603 million), Bank of China Securities (-519 million), and Industrial Fulian (-452 million) [1] Group 2 - The article provides a detailed list of the top 20 stocks with the largest capital outflows, indicating a trend of investor withdrawal from these companies [1] - The total outflow amounts for the listed companies range from 2.42 billion to 15.18 billion, highlighting a significant shift in investor sentiment [1] - The data reflects a broader market trend that may impact future investment strategies and stock performance [1]

Group 1 - The Hong Kong stock market experienced a rise and then a pullback, with the Hang Seng Index reaching a new high [1] - The National Healthcare Security Administration is publishing a list of drugs that have passed preliminary review for the "2025 National Medical Insurance Directory and Commercial Insurance Innovative Drug Directory," which will enter expert review and negotiation stages [1][2] - The Hong Kong Innovative Drug Selected ETF (520690) saw a nearly 2.5% increase, with a trading volume exceeding 20 million and a turnover rate over 5%, indicating strong market interest [1] Group 2 - The dual-track policy of basic medical insurance and commercial insurance for innovative drugs signals a payment closure model, suggesting that "true innovation is easier to scale" [2] - The performance of innovative drugs is expected to be positively impacted by the dual-track payment system and significant business development opportunities, leading to a systematic revaluation of the Chinese innovative drug sector [2] - The Hang Seng Medical ETF (513060) is benefiting from the dual advantages of technology penetration and market expansion, particularly in AI healthcare and innovative drug companies [3]